COVID Antibody Test IgG/IgM

Next generation

The Assured Screening Network offers a highly sensitive antibody test utilising Quotient’s high-throughput MosaiQ™ platform.

Tests are available across the UK and Ireland via our network of clinical test partners.

This is in addition to and complements PCR screening for active COVID-19 infection.

High accuracy, rapid turnaround COVID-19 antibody testing across UK & Ireland:

Dual Antibody Detection
Detects at an Early Stage of Infection
IgG and IgM Response Detection to SARS-CoV-2
High Accuracy COVID-19 Antibody Test
Best in Class in IgG and IgM Detection
Rapid Turnaround – Result to Clinic in 24 hours of Sample Receipt

The Test

The test is designed to detect both IgG and IgM response to SARS-CoV-2 at an early stage of infection. Evidence from studies has shown that people can be IgM positive while not IgG positive.

Detecting antibodies with 100% sensitivity, the MosaiQ™ equipment can process up to 3,000 samples a day utilising our in-house sample collection network. We are the only laboratory to provide antibody and PCR sample turnaround in less than 24 hours from collection* throughout the UK and Republic of Ireland.

This CE-IVD certified COVID antibody test is available throughout the UK and Ireland via our network of specialist phlebotomy partners. Already available in the US, Switzerland, Denmark, Spain, France and the United States, now launching in UK and Ireland.

*For collections provided by Honeyman Group Logistics (not third party couriers).

Clinical Utility

The MosaiQ™ COVID-19 Antibody Microarray was CE marked on 01 May 2020. With a 100% sensitivity and 99.8% specificity claim, the test has a best in class performance.

The MosaiQ instrument has all relevant medical diagnostic device approvals and the microarray manufacturing facility is ISO 13485 certified.

100% Sensitivity
99.8% Specificity
ISO 13485 Certified
CE-IVD Approved

Benefits of COVID-19 Antibody Testing

Antibody testing is important as it can indicate the presence of Covid-19 related antibodies resulting from past or recent infection, allowing immunity rates to be assessed. Using COVID-19 antibody testing solutions to assess an individual’s potential immunity to the disease can help clinicians ultimately determine who can return to work and daily life amid the COVID-19 pandemic.

As the COVID-19 pandemic continues to disrupt every aspect of normality, affecting millions worldwide, Honeyman Group is committed to help those with immunity return to work, particularly healthcare workers on the frontline.

Who can benefit from IgG and IgM Antibody Testing?

Businesses
Occupational Health Teams
Combined programmes utilising both Antibody Testing and PCR Screening
Research and Development Studies
Healthcare Professionals
Public Organisations

COVID Antibody testing:

Franz Walt

Chief Executive Officer, Quotient

Antibody testing – the ability to quickly test if people have developed antibodies to COVID-19– is critical in helping the UK move out of lockdown, restarting the economy and continuing to fight this pandemic. We are proud to be working with Honeyman.

Tom Honeyman

MD, Assured Screening
Honeyman Group

Existing approved test methods used within the UK provide for IgG antibody detection only, but research has shown that not everyone has this reaction. Quotient’s MosaiQ™ COVID-19 Antibody Microarray additionally picks-up the instances in which people have an IgM response.

Ed Farrell

Chief Operating Officer, Quotient

MosaiQ was developed in the UK, in Edinburgh, and Switzerland and we believe it is one of the most accurate and fastest tests on the market. We are talking to Governments and laboratories across the Continent and are delighted about the positive response we have been getting.